Announcements
- Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
- Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
- Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
- Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
- Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024
- Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
- Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités
- Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
More ▼
Key statistics
On Thursday, Inventiva SA (6IV:DUS) closed at 3.15, 18.20% above the 52 week low of 2.67 set on May 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.15 |
---|---|
High | 3.15 |
Low | 3.15 |
Bid | 3.29 |
Offer | 3.37 |
Previous close | 3.16 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 173.44m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of May 30 2024 07:11 BST.
More ▼